Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy CEL-SCI Corporation (CVM) stocks in Canada

Learn how to easily invest in CEL-SCI Corporation stocks.

CEL-SCI Corporation is a biotechnology business based in the US. CEL-SCI Corporation stocks (CVM.US) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $9.33 – a decrease of 3.26% over the previous week. CEL-SCI Corporation employs 0 staff and has a trailing 12-month revenue of around $28,558.

How to buy shares in CEL-SCI Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CVM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

CEL-SCI Corporation stock price (NYSE MKT:CVM)

Use our graph to track the performance of CVM stocks over time.

CEL-SCI Corporation shares at a glance

Information last updated 2022-01-25.
Latest market close$5.63
52-week range$5.31 - $40.91
50-day moving average $8.58
200-day moving average $12.91
Wall St. target price$13.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.90

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy CEL-SCI Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

CEL-SCI Corporation price performance over time

Historical closes compared with the close of $5.63 from 2022-01-26

1 week (2022-01-21) -0.18%
1 month (2021-12-27) -27.91%
3 months (2021-10-26) -50.44%
6 months (2021-07-28) -32.17%
1 year (2021-01-28) -70.98%
2 years (2020-01-28) -60.30%
3 years (2019-01-28) 104.73%
5 years (2017-01-27) 4,560.60%

CEL-SCI Corporation financials

Revenue TTM $28,558
Gross profit TTM $-23,108,897
Return on assets TTM -38.87%
Return on equity TTM -9627.99%
Profit margin 0%
Book value $1.31
Market capitalisation $251.7 million

TTM: trailing 12 months

CEL-SCI Corporation share dividends

We're not expecting CEL-SCI Corporation to pay a dividend over the next 12 months.

Have CEL-SCI Corporation's shares ever split?

CEL-SCI Corporation's shares were split on a 1:25 basis on 14 June 2017. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CEL-SCI Corporation shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for CEL-SCI Corporation shares which in turn could have impacted CEL-SCI Corporation's share price.

CEL-SCI Corporation share price volatility

Over the last 12 months, CEL-SCI Corporation's shares have ranged in value from as little as $5.31 up to $40.91. A popular way to gauge a stock's volatility is its "beta".

CVM.US volatility(beta: 2.05)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while CEL-SCI Corporation's is 2.0512. This would suggest that CEL-SCI Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.

CEL-SCI Corporation overview

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia. .

Stocks similar to CEL-SCI Corporation

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site